{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:26:39Z","timestamp":1790799999814,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009580","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T00:00:00Z","timestamp":1445731200000}}],"reference-count":72,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009580.pub2","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T14:36:19Z","timestamp":1445783779000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Fibrates for secondary prevention of cardiovascular disease and stroke"],"prefix":"10.1002","volume":"2018","author":[{"given":"Deren","family":"Wang","sequence":"first","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Tao","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Hao","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,25]]},"reference":[{"issue":"17","key":"10.1002\/14651858.CD009580.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0021-9150(72)90067-6","article-title":"Controlled trial of clofibrate in cerebral vascular disease","volume":"15","author":"Acheson","year":"1972","journal-title":"Atherosclerosis"},{"issue":"9005","key":"10.1002\/14651858.CD009580.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson","year":"1996","journal-title":"The Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009580.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0268-9499(97)80044-6","article-title":"BECAIT Bezafibrate following acute myocardial infarction: Important findings from the Bezafibrate Coronary Atherosclerosis Intervention Trial","volume":"11","author":"Nilsson","year":"1997","journal-title":"Fibrinolysis and Proteolysis"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/eurheartj\/17.suppl_F.37","article-title":"Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)","volume":"17 Suppl F","author":"Faire","year":"1996","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Goldbourt U Behar S Reicher-Reiss H Agmon J Kaplinsky E Graff E Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial) The American Journal of Cardiology 1993 909\u201315","DOI":"10.1016\/0002-9149(93)90905-R"},{"issue":"4","key":"10.1002\/14651858.CD009580.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jacc.2007.09.048","article-title":"Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial","volume":"51","author":"Goldenberg","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD009580.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 2000 21 7","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 1975 360 81","DOI":"10.1001\/jama.1975.03240160024021"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Derosa G Cicero AEG Bertone G Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial Clinical Therapeutics 2004 1599 607","DOI":"10.1016\/j.clinthera.2004.10.008"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/07853899309147855","article-title":"Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population","volume":"25","author":"Frick","year":"1993","journal-title":"Annals of Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Meade T Zuhrie R Cook C Bezafibrate in men with lower extremity arterial disease: randomised controlled trial BMJ 2002 1139","DOI":"10.1136\/bmj.325.7373.1139"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0014|cit14","first-page":"195\u2013204","article-title":"Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease","volume":"2","author":"Meade TW for the British Medical Research Council General Practice Research Framework and participating vascular clinics","year":"2001","journal-title":"Current Controlled Trials Cardiovascular Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009580.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/bmj.4.5790.767","article-title":"Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region","volume":"4","year":"1971","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4684-7547-0_21","article-title":"Ischemic heart disease: a secondary prevention trial using clofibrate (Atromid-S)","volume":"26","author":"Oliver","year":"1972","journal-title":"Advances in Experimental Medicine & Biology"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Research Committee of the Scottish Society of Physicians Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians British Medical Journal 1971 775 84","DOI":"10.1136\/bmj.4.5790.775"},{"issue":"13","key":"10.1002\/14651858.CD009580.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJM197209282871327","article-title":"Clofibrate for the treatment of occlusive cerebrovascular disease","volume":"287","author":"Hirsch","year":"1972","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"The Veterans Administration Cooperative Study Group The treatment of cerebrovascular disease with clofibrate Stroke 1973 684 93","DOI":"10.1161\/01.STR.4.4.684"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Robins SJ Collins D Wittes JT Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 2001 1585 91","DOI":"10.1001\/jama.285.12.1585"},{"issue":"23","key":"10.1002\/14651858.CD009580.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"103","author":"Rubin","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD009580.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney International"},{"issue":"9260","key":"10.1002\/14651858.CD009580.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","author":"Diabetes Atherosclerosis Intervention Study Investigators","year":"2001","journal-title":"The Lancet"},{"issue":"9500","key":"10.1002\/14651858.CD009580.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"The FIELD study investigators","year":"2005","journal-title":"The Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ahj.2011.12.004","article-title":"Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"163","author":"Tonkin","year":"2012","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/ATVBAHA.113.302926","article-title":"Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)","volume":"34","author":"Davidson","year":"2014","journal-title":"Arteriosclerosis, Thrombosis & Vascular Biology"},{"issue":"4","key":"10.1002\/14651858.CD009580.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.14.4.308","article-title":"Diabetes intervention study. Multi-intervention trial in newly diagnosed NIDDM","volume":"14","author":"Hanefeld","year":"1991","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1002\/14651858.CD009580.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-511X-12-133","article-title":"The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome","volume":"12","author":"Li","year":"2013","journal-title":"Lipids in Health & Disease"},{"issue":"5","key":"10.1002\/14651858.CD009580.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/17843286.1975.11717029","article-title":"A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia","volume":"30","author":"Rottiers","year":"1975","journal-title":"Acta Clinica Belgica"},{"issue":"4","key":"10.1002\/14651858.CD009580.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diacare.21.4.641","article-title":"Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study","volume":"21","author":"Elkeles","year":"1998","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0035|cit35","unstructured":"Chong Kun Dang Pharmaceutical Efficacy and safety of fenofibrate added on to atorvastatin compared with atorvastatin in mixed hypercholesterolemic patient (CKD-337) http:\/\/clinicaltrials.gov\/show\/NCT01956201 2013"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0036|cit36","unstructured":"Oh HK Efficacy and safety of fenofibrate added on to atorvastatin compared with atorvastatin http:\/\/clinicaltrials.gov\/show\/NCT019562011 2013"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0037|cit37","unstructured":"Koval O Simvastatin and fenofibrate vs simvastatin alone in patients with type 2 diabetes mellitus and acute coronary syndrome https:\/\/clinicaltrials.gov\/show\/NCT02015988 2013"},{"issue":"1","key":"10.1002\/14651858.CD009580.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Karen","year":"2011","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD009580.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"6A","key":"10.1002\/14651858.CD009580.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"19C","DOI":"10.1016\/j.amjcard.2006.11.017","article-title":"Expert commentary: the safety of fibrates in lipid-lowering therapy","volume":"99","author":"Brown","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD009580.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1161\/01.ATV.13.5.702","article-title":"Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia","volume":"13","author":"Caslake","year":"1993","journal-title":"Arteriosclerosis and Thrombosis: a Journal of Vascular Biology\/American Heart Association"},{"issue":"20","key":"10.1002\/14651858.CD009580.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"issue":"1-2","key":"10.1002\/14651858.CD009580.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-M","article-title":"Lipids and risk of coronary heart disease. The Framingham Study","volume":"2","author":"Castelli","year":"1992","journal-title":"Annals of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD009580.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.ATV.13.5.712","article-title":"Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment","volume":"13","author":"Graaf","year":"1993","journal-title":"Arteriosclerosis and Thrombosis: a Journal of Vascular Biology\/American Heart Association"},{"issue":"11","key":"10.1002\/14651858.CD009580.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"European Heart Journal"},{"issue":"7109","key":"10.1002\/14651858.CD009580.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"9005","key":"10.1002\/14651858.CD009580.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson","year":"1996","journal-title":"The Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009580.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","article-title":"The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy","volume":"6","author":"Fazio","year":"2004","journal-title":"Current Atherosclerosis Reports"},{"issue":"9500","key":"10.1002\/14651858.CD009580.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009580.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0051|cit51","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD009580.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"Journal of Cardiovascular Risk"},{"issue":"1","key":"10.1002\/14651858.CD009580.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society","year":"2014","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1875\u201384","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"335\u201342","DOI":"10.1007\/s11936-011-0128-7","article-title":"The use of fibric acid derivatives in cardiovascular prevention","volume":"13","author":"Khoury","year":"2011","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0057|cit57","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011"},{"issue":"8019","key":"10.1002\/14651858.CD009580.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(77)92274-7","article-title":"The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study","volume":"1","author":"Miller","year":"1977","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"g4356","DOI":"10.1136\/bmj.g4356","article-title":"Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance","volume":"349","author":"Rabar","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"70\u20132","DOI":"10.1038\/nrcardio.2010.208","article-title":"Atherosclerosis in 2010: New therapeutic insights","volume":"8","author":"Nissen","year":"2011","journal-title":"Nature Reviews. Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","author":"Nordmann","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009580.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-199904000-00009","article-title":"Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging","volume":"10","author":"Pineda Torra","year":"1999","journal-title":"Current Opinion in Lipidology"},{"issue":"4","key":"10.1002\/14651858.CD009580.pub2-BIB0063|cit63","first-page":"e18","article-title":"Heart disease and stroke statistics-2011 update: A report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"493\u20138","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD009580.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.ATV.12.3.286","article-title":"Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat","volume":"12","author":"Staels","year":"1992","journal-title":"Arteriosclerosis and Thrombosis"},{"issue":"19","key":"10.1002\/14651858.CD009580.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD009580.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199108083250601","article-title":"A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction","volume":"325","author":"Stampfer","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009580.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2337\/diacare.21.4.477","article-title":"Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study","volume":"21","author":"Tikkanen","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"103","author":"Bloomfield","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0070|cit70","unstructured":"World Health Organization Cardiovascular disease http:\/\/www.who.int\/cardiovascular_diseases\/priorities\/en\/"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0071|cit71","unstructured":"World Health Organization Global status report on noncommunicable diseases 2014 Geneva: World Health Organization; 2014"},{"key":"10.1002\/14651858.CD009580.pub2-BIB0072|cit72","unstructured":"World Health Organization Cardiovascular diseases (CVDs) [Updated January 2015] http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/ 2015"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009580.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T03:48:22Z","timestamp":1743997702000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009580.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,25]]},"references-count":72,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009580.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,25]]}}}